AnaptysBio’s Pivotal Legal Battle and Corporate Split on the Horizon

Shares of AnaptysBio are trading marginally lower than the previous session’s close. The company’s valuation is currently tethered to a high-stakes legal dispute with Tesaro, now part of GSK, concerning royalties for the cancer drug Jemperli. A trial scheduled for July is anticipated to bring substantial clarity to the financial implications of this case.

Financial Health and Strategic Reorganization

According to preliminary figures, AnaptysBio reported a strong liquidity position of approximately $310 million in cash and investments as of December 31, 2025. This financial backbone supports the company’s ambitious plan to separate into two publicly traded entities by the end of 2026. The split aims to create a dedicated Royalty Management Company to oversee royalty cash flows and a distinct Biopharma Company focused on advancing its immunology pipeline, including rosnilimab and ANB033. The strategic objective is to unlock the standalone value of the royalty stream while providing the biopharma unit with capital to fund operations for a minimum of two years.

The Core Legal Dispute: Jemperli Royalties

The central legal confrontation, set for trial in the Delaware Chancery Court from July 14 to 17, 2026, alleges breaches of exclusivity clauses and financial obligations under a licensing agreement. AnaptysBio has moved to partially dismiss Tesaro’s counterclaims in an effort to narrow the scope of the litigation. The court’s ruling will directly determine the future payment streams from Jemperli royalties, which are projected to reach peak annual revenues exceeding $390 million, and thus critically impact their valuation.

Should investors sell immediately? Or is it worth buying AnaptysBio?

Pipeline Focus and Analyst Sentiment

The clinical pipeline remains active despite the discontinuation of a rosnilimab study in ulcerative colitis. Key upcoming milestones include a clinical update for rosnilimab in rheumatoid arthritis in the first half of 2026 and Phase 1b data for ANB033, a CD122-targeting asset, expected in the fourth quarter of 2026. ANB101 is also progressing in Phase 1a studies. While market experts maintain a generally positive outlook with an average price target of $67.92, investor sentiment remains cautious due to the ongoing legal uncertainty and corporate restructuring. The stock continues to trade within its 52-week range of $12.21 to $52.47.

Critical Upcoming Catalysts

Two major near-term catalysts will shape the investment narrative. The first half of 2026 will bring the rheumatoid arthritis update for rosnilimab, which will influence the need for partnership deals or non-dilutive financing to advance into Phase 3. Immediately following, the July 14-17 court proceedings will address the Jemperli royalty dispute. The outcomes of these events will be decisive in assessing the value of the royalty portfolio and the future prospects of the planned Biopharma Company.